Jefferies Sets a $28 PT for enGene Holdings Inc. (ENGN)

We recently published an article titled 10 Best Low Volatility Canadian Stocks to Buy.

On January 30, Jefferies initiated coverage of enGene Holdings Inc. (NASDAQ:ENGN) with a Buy rating and a $28 price target, highlighting the company’s ongoing pivotal study in high-risk non-muscle invasive bladder cancer (NMIBC), with a key data update expected in the second half of 2026.

enGene Holdings Inc. (NASDAQ:ENGN) is positioning itself as a differentiated player in the bladder cancer treatment landscape as it advances detalimogene voraplasmid, its lead non-viral gene therapy candidate, into late-stage development. Beyond clinical momentum, enGene has strengthened its financial footing. On January 21, the company expanded its debt facility with Hercules Capital to up to $125 million, securing additional non-dilutive financing to support its planned Biologics License Application and potential U.S. commercialization. The amended agreement provides $25 million immediately to refinance existing debt and up to $100 million in additional tranches tied to clinical, regulatory, and commercial milestones. This capital structure enhances flexibility as enGene transitions from a development-stage biotech to a potential commercial-stage company in a competitive but high-need oncology market.

Founded in 1999 and headquartered in Saint-Laurent, Quebec, enGene Holdings Inc. (NASDAQ:ENGN) leverages its proprietary Dually Derivatized Chitosan (DDX) platform to develop non-viral genetic medicines targeting mucosal diseases. With pivotal data on the horizon, strengthened liquidity, and a differentiated therapeutic approach, enGene represents a high-risk, high-reward opportunity for investors seeking exposure to innovative oncology platforms with meaningful upside potential.

While we acknowledge the potential of ENGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 8 Up and Coming Streaming Companies and Services and 9 High Growth Canadian Stocks to Buy

Disclosure: None.